Transcutaneous PO2 and PCO2 during surfactant therapy in newborn infants with idiopathic respiratory distress syndrome.
We conclude that surfactant treatment in newborn infants with IRDS results in decrease in TcPO2 and an increase in TcPO2 within minutes. The surfactant treatment procedure used in this study was not associated with hypoxemia. During surfactant treatment monitoring of TcPO2 and TcPCO2 is absolutely necessary.
Oetomo
S B
SB
Dept. Paediatrics, University Hospital, Groningen, The Netherlands.
Robertson
B
B
Okken
A
A
D001785:Blood Gas Monitoring, Transcutaneous; D006801:Humans; D007231:Infant, Newborn; D010102:Oxygen Inhalation Therapy; D011663:Pulmonary Surfactants / Q000008:administration & dosage*; D012127:Respiratory Distress Syndrome, Newborn / Q000097:blood / Q000628:therapy*
D011663:Pulmonary Surfactants